Published in AJNR Am J Neuroradiol on May 27, 2009
Heterogeneous cerebral vasoreactivity dynamics in patients with carotid stenosis. PLoS One (2013) 0.84
A case study of magnetic resonance imaging of cerebrovascular reactivity: a powerful imaging marker for mild traumatic brain injury. Brain Inj (2014) 0.83
Isolated Subarachnoidal Hemorrhage following Carotid Endarterectomy. Case Rep Neurol (2010) 0.79
Endovascular treatment of peripheral arterial injury with covered stents: an experimental study in pigs. Clinics (Sao Paulo) (2011) 0.77
Graph theoretical analysis of functional networks and its relationship to cognitive decline in patients with carotid stenosis. J Cereb Blood Flow Metab (2015) 0.77
Effect of carotid artery stenting on cerebral blood flow: evaluation of hemodynamic changes using arterial spin labeling. Neuroradiology (2012) 0.77
Assessing Cerebrovascular Reactivity in Carotid Steno-Occlusive Disease Using MRI BOLD and ASL Techniques. Radiol Res Pract (2012) 0.76
Using Flat-Panel Perfusion Imaging to Measure Cerebral Hemodynamics: A Pilot Feasibility Study in Patients With Carotid Stenosis. Medicine (Baltimore) (2016) 0.75
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis (2010) 1.88
Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer (2003) 1.83
Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther (2004) 1.72
Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest (2003) 1.71
Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol (2004) 1.66
Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res (2006) 1.62
A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med (2005) 1.61
Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine (2003) 1.56
Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand (2006) 1.54
Prospects of RNA interference therapy for cancer. Gene Ther (2006) 1.52
Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines (2007) 1.50
Improved optical transmission and current matching of a triple-junction solar cell utilizing sub-wavelength structures. Opt Express (2010) 1.49
Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. Transfusion (2003) 1.47
Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res (2007) 1.43
Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells. Gene Ther (2007) 1.40
Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther (2008) 1.40
Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res (2007) 1.39
Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine (2009) 1.38
DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency. Mol Ther (2007) 1.37
Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest (2012) 1.37
Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res (2005) 1.32
Focus on endometrial and cervical cancer. Cancer Cell (2004) 1.32
Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol (2004) 1.30
Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res (2008) 1.29
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27
Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope. Gene Ther (2005) 1.26
Vaccination to prevent and treat cervical cancer. Hum Pathol (2004) 1.25
Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther (2008) 1.24
Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice. Gene Ther (2006) 1.24
A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumors. Vaccine (2006) 1.24
Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res (2004) 1.24
Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis. Br J Cancer (2004) 1.24
Monitoring the trafficking of adoptively transferred antigen- specific CD8-positive T cells in vivo, using noninvasive luminescence imaging. Hum Gene Ther (2007) 1.23
Activation of Akt as a mechanism for tumor immune evasion. Mol Ther (2008) 1.22
Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther (2008) 1.22
Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies. J Immunol (2003) 1.21
Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res (Phila) (2011) 1.21
Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18
Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. Oncogene (2009) 1.17
Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther (2002) 1.17
Control of human mesothelin-expressing tumors by DNA vaccines. Gene Ther (2007) 1.17
Isolated ocular motor nerve palsy in dural carotid-cavernous sinus fistula. Eur J Neurol (2006) 1.15
Cancer vaccination drives Nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype. Cancer Res (2012) 1.13
Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine (2007) 1.12
Therapeutic HPV DNA vaccines. Immunol Res (2010) 1.12
Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res (2003) 1.10
Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther (2005) 1.10
Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunol Immunother (2012) 1.10
A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. Gene Ther (2006) 1.08
Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice. Gene Ther (2006) 1.08
Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency. Vaccine (2007) 1.07
Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination. J Mol Med (Berl) (2008) 1.04
Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol Immunother (2008) 1.04
Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine (2004) 1.03
Clinical relevance of musical murmurs in color-coded carotid and transcranial duplex sonographies. AJNR Am J Neuroradiol (2006) 1.02
Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Infect Immun (2008) 1.02
DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med (2007) 1.02
Connective tissue growth factor modulates oral squamous cell carcinoma invasion by activating a miR-504/FOXP1 signalling. Oncogene (2011) 1.02
Efficient delivery of DNA vaccines using human papillomavirus pseudovirions. Gene Ther (2010) 1.02
Inactivation of viruses by coherent excitations with a low power visible femtosecond laser. Virol J (2007) 1.02
Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. Mol Ther (2010) 1.01
HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res (2007) 1.01
Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. Crit Rev Oral Biol Med (2003) 1.01
Microbiological characteristics of clinical isolates of Cryptococcus neoformans in Taiwan: serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility. Clin Microbiol Infect (2009) 1.01
Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum Gene Ther (2005) 1.01
DNA vaccines for cancer. IDrugs (2003) 1.00
Role of the CC chemokine receptor 9/TECK interaction in apoptosis. Apoptosis (2002) 1.00
Ectopic expression of X-linked lymphocyte-regulated protein pM1 renders tumor cells resistant to antitumor immunity. Cancer Res (2010) 0.99
Photonic approach to the selective inactivation of viruses with a near-infrared subpicosecond fiber laser. J Biomed Opt (2010) 0.99
Transfusion-associated microchimerism. Vox Sang (2007) 0.99
Dose-dense chemotherapy improves mechanisms of antitumor immune response. Cancer Res (2012) 0.99
MR imaging findings of medulla oblongata involvement in posterior reversible encephalopathy syndrome secondary to hypertension. AJNR Am J Neuroradiol (2008) 0.98
HPV DNA vaccines. Front Biosci (2003) 0.98
Improving DNA vaccine potency by linking Marek's disease virus type 1 VP22 to an antigen. J Virol (2002) 0.98
Scoring systems for 6-month mortality in critically ill cirrhotic patients: a prospective analysis of chronic liver failure - sequential organ failure assessment score (CLIF-SOFA). Aliment Pharmacol Ther (2014) 0.98
Inactivation of viruses by laser-driven coherent excitations via impulsive stimulated Raman scattering process. J Biomed Opt (2007) 0.98
The prevalence of premenstrual dysphoric disorder in a randomly selected group of urban and rural women. Psychol Med (2008) 0.98
In vivo microRNA-155 expression influences antigen-specific T cell-mediated immune responses generated by DNA vaccination. Cell Biosci (2011) 0.97
Molecular epidemiology of human papillomavirus. J Formos Med Assoc (2008) 0.97
FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. Br J Dermatol (2005) 0.97
Treatment with cyclooxygenase-2 inhibitors enables repeated administration of vaccinia virus for control of ovarian cancer. Mol Ther (2009) 0.97
Transcription factor SOX-5 enhances nasopharyngeal carcinoma progression by down-regulating SPARC gene expression. J Pathol (2008) 0.97
CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Ther (2003) 0.97
Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis. Clin Radiol (2007) 0.97
Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs (2012) 0.96
Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers. Oncogene (2007) 0.96
Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents. Hum Gene Ther (2011) 0.96
Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth. Adv Healthc Mater (2013) 0.95
Time dependent validity in the diagnosis of brain death using transcranial Doppler sonography. J Neurol Neurosurg Psychiatry (2006) 0.95
Gap opening and orbital modification of superconducting FeSe above the structural distortion. Phys Rev Lett (2012) 0.95
Cluster intradermal DNA vaccination rapidly induces E7-specific CD8+ T-cell immune responses leading to therapeutic antitumor effects. Gene Ther (2008) 0.95
Development of a DNA vaccine targeting Merkel cell polyomavirus. Vaccine (2011) 0.95
Nonlinear bio-photonic crystal effects revealed with multimodal nonlinear microscopy. J Microsc (2002) 0.95
Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies. J Biomed Sci (2005) 0.95
Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis. Eur J Immunol (2009) 0.94
A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Ther (2008) 0.94